Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 26:33:100581.
doi: 10.1016/j.gore.2020.100581. eCollection 2020 Aug.

Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

John K Chan  1 , David S Lakomy  2 , Yassmina McDonald  1 , Daniel S Kapp  3
Affiliations

Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

John K Chan et al. Gynecol Oncol Rep. .

Erratum in

Abstract

•Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options.•Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer.•Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient 1 (A) December 2017 CT of right pulmonary nodule, (B) December 2018 CT of drastic decrease in right pulmonary nodule size following pembrolizumab therapy. Patient 2 (C) March 2018 CT showing sclerotic rib lesion, (D) April 2019 CT showing decrease in its size following radiation therapy and pembrolizumab therapy.
See this image and copyright information in PMC

References

    1. Bestvina C.M., Fleming G.F. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21:1250–1259. doi: 10.1634/theoncologist.2016-0062. - DOI - PMC - PubMed
    1. Dudley J.C., Lin M.-T., Le D.T., Eshleman J.R. Microsatellite instability as a biomarker for PD-1 blockade. Clin. Can. Res. 2016;22:813–820. doi: 10.1158/1078-0432.CCR-15-1678. - DOI - PubMed
    1. Garcia C., Ring K.L. The role of PD-1 checkpoint inhibition in gynecologic malignancies. Curr. Treat. Options in Oncol. 2018;19:70. doi: 10.1007/s11864-018-0593-2. - DOI - PubMed
    1. Le D.T., Durham J.N., Smith K.N., Wang H., Bartlett B.R., Aulakh L.K., Lu S., Kemberling H., Wilt C., Luber B.S., Wong F., Azad N.S., Rucki A.A., Laheru D., Donehower R., Zaheer A., Fisher G.A., Crocenzi T.S., Lee J.J., Greten T.F., Duffy A.G., Ciombor K.K., Eyring A.D., Lam B.H., Joe A., Kang S.P., Holdhoff M., Danilova L., Cope L., Meyer C., Zhou S., Goldberg R.M., Armstrong D.K., Bever K.M., Fader A.N., Taube J., Housseau F., Spetzler D., Xiao N., Pardoll D.M., Papadopoulos N., Kinzler K.W., Eshleman J.R., Vogelstein B., Anders R.A., Diaz L.A. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733. - DOI - PMC - PubMed
    1. Makker Vicky, Green Angela K., Wenham Robert M., Mutch David, Davidson Brittany, Miller David Scott. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynaecol. Oncol. Res. Pract. 2017;4(1) doi: 10.1186/s40661-017-0056-7. - DOI - PMC - PubMed

LinkOut - more resources